Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma

This study tests a three-drug combination — orelabrutinib, rituximab, and methotrexate — for newly diagnosed primary central nervous system (CNS) lymphoma, a rare type of lymphoma (blood cancer) that occurs in the brain or spinal cord. Researchers want to see if this combination is effective and safe. **You may be eligible if...** - You are age 18 to 75 - You have been diagnosed with primary CNS lymphoma confirmed by biopsy - You have not previously received chemotherapy or radiation for this condition (steroids alone are acceptable) - Your tumor can be measured on an MRI scan - Your overall health and organ function are adequate **You may NOT be eligible if...** - You have received prior chemotherapy or radiation for CNS lymphoma - You have serious heart, kidney, or liver problems - You have an active infection (including HIV or hepatitis B/C) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.